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Functional constipation is a common clinical complaint of patients with unsatisfactory treatment
outcome. We designed this study to evaluate the efﬁciency of a traditional herbal preparation (Lax-Asab)
in treating chronic constipation. In this double-blind, randomized, placebo-controlled clinical trial,
participants with chronic constipation (n ¼ 48) were randomly selected to receive either the Lax-Asab
powder (n ¼ 24) or placebo (n ¼ 24) on alternative days for 4 weeks. The Lax-Asab powder contains
equal amounts of Cassia angustifolia Vahl. (狹葉番瀉葉 xia ye fan xie ye), Mentha piperita L. (胡椒薄荷 hú
jiao bo he), Zingiber ofﬁcinale Rosc. (生薑 sheng jiang), Glycyrrhiza glabra L. (甘草 gan cǎo). A total of 40
patients completed the study. We determined the severity of constipation based on defecation frequency
(per week) and defecation difﬁculties. Of the total of 48 patients who participated, 40 completed the trial
[24 men (60%), mean age, 21.0 ± 4.2 years; 16 women (40%), mean age, 20.1 ± 4.3 years]. The mean of
weekly defecation frequency increased in both groups; from 1.8 ± 0.41 to 4.8 ± 1.12 times in patients who
received Lax-Asab and from 1.7 ± 0.44 to 2.2 ± 0.61 times in patients who received placebo. A time
etreatment interaction showed that this increase was signiﬁcantly higher in the intervention group.
Defecation difﬁculties improved signiﬁcantly more in patients who received Lax-Asab than patients who
received placebo. There was no statistically signiﬁcant difference between the two groups with regard to
the side effects observed. This study conﬁrms the efﬁcacy and tolerability of an Iranian herbal prepa-
ration, Lax-Asab, in treating patients with chronic functional constipation.
Copyright © 2014, Center for Food and Biomolecules, National Taiwan University. Production and hosting
by Elsevier Taiwan LLC. All rights reserved.1. Introduction
Constipation is a common complaint encountered by physicians,
and women are two times as likely to report constipation than
men.1 Constipation is commonly multifactorial and can result from
metabolic, endocrine, or neurological disorders, or from the
adverse effect of medications.2 In functional defecation disorders,3
patients perceived constipation as difﬁculties in defecating or the
presence of hard stools despite a normal evacuation rate.2 The
prevalence rate (usually on the higher side) of constipation varies
considerably due to different methods applied and differences in
study populations. The prevalence of constipation in the IranianGolgashtave, Tabriz, East
omi).
for Food and Biomolecules,
molecules, National Taiwan Univepopulation is reported to be 1.4e37%, and the prevalence of func-
tional constipation is reported to be 2.4e11.2%.4
Chronic constipation impairs health-related quality of life, and
thus, appropriate management is very important.3,5 A recent
population-based study estimated the economic burden of func-
tional bowel disorders (including functional constipation) in Iran
and reported a heavy ﬁnancial burden on the Iranian national
health system.6
Constipation, especially when chronic and severe, can result in
complications such as fecal impactions, hemorrhoid and rectal
bleeding, colorectal obstruction, colorectal ulcers, rectal prolapse,
anal ﬁssures, and pelvic wall insufﬁciency,7 thereby increasing the
burden of the disorder on the patient's health. Thus, constipation is
considered a common clinical problem as well. A long-lasting
management of chronic constipation usually begins with lifestyle
modiﬁcations and increased intake of dietary ﬁbers and ﬂuids alone
or in combination with an osmotic laxative. Polyethylene glycol,
sodium picosulfate, bisacodyl, prucalopride, lubiprostone, andrsity. Production and hosting by Elsevier Taiwan LLC. All rights reserved.
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treating chronic functional constipation.8 Although there are also
other preparations used for treating chronic functional con-
stipation, only limited evidence is available to support their efﬁ-
cacy. Thus, their use may be restricted to patients who fail to
respond to conventional treatments. Many patients are still treated
empirically as there is a lack of an evidence-based algorithm so far.9
The high costs and widespread complications associated with
chemical drugs force patients to consume alternative medication,
which sometimes have higher efﬁcacy and lower side effects and
cost. In Western European countries and the United States,
approximately 8e50% of individuals use alternative medication; in
fact, this rate is even higher in developing countries.10 Patients
consider herbal medicines appropriate because they are easy to
obtain, affordable, and have fewer side effects.10 We designed this
study to evaluate a herbal preparation (Lax-Asab), which is tradi-
tionally used for the treatment of chronic constipation in some
regions of Iran and is well-known for higher efﬁcacy, lower side
effects, and lower cost in comparisonwith other currently available
chemical and herbal remedies.
2. Materials and methods
2.1. Study patients
This double-blind, randomized control clinical trial was carried
out at the outpatient clinic of Tabriz University of Medical Sciences,
Iran, during 2011e2012. The study protocol was in accordance withFig. 1. Flow diagram othe Declaration of Helsinki and was approved by the Regional Ethic
Committee on August 20, 2010 (Reference No. 904). The study is
also registered as a clinical trial in the Iranian Registry of Clinical
Trials (www.irct.ir; Registration No. IRCT201105046388N1). All
participants gave written informed consent before participation.
All patients diagnosed by a gastroenterologist to have func-
tional constipation according to the Rome III criteria (for at least 3
months) were included if they agreed to avoid using any laxative
medication for 1 week before beginning the study. A thorough
physical examination was performed, and patients' medical his-
tory and biochemical parameters (including liver, renal, and thy-
roid function tests) were reviewed and collected before the trial.
Any general reasons for constipation mentioned in the medical
history were excluded. Imaging or additional evaluations were
carried out based on the clinical judgment of the attending
gastroenterologist.
Participants with a history of organic gastrointestinal (GI) dis-
orders (including cancer and celiac disease); renal, hepatic, cardiac,
pulmonary, neurologic, and hematologic diseases; malignancy;
inﬂammatory bowel disease; drugs or alcohol-use problems; hy-
persensitivity to herbal preparations; pregnancy; lactation; history
of GI bleeding; emergence of intolerable, serious drug side effects;
and those noncompliant to the study protocol were excluded from
the study. All of the patients were allowed to leave the study at any
time and would subsequently receive standard care. Medications
that may affect GI motility were not allowed during the study
period (e.g., antidepressants, narcotic analgesics, and medications
with an anticholinergic effect).f the study trial.
Table 1
Outcome of treatment in patients receiving Lax-Asab or placebo.
Lax-Asab Placebo p OR 95% conﬁdence
interval
Hard stool 2 (10%) 20 (100%) <0.001 10 20.68e37.23
Feeling of obstruction 1 (5%) 19 (95%) <0.001 20 2.96e135.1
Need for excessive
straining
3 (15%) 20 (100%) <0.001 6.66 2.34e18.92
Sense of incomplete
bowel evacuation
3 (15%) 20 (100%) <0.001 6.66 2.34e18.92
OR ¼ odds ratio.
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The participants were randomized using the RandList analyzer
software. Selected patients received either Lax-Asab (Lax-Asab
group) or placebo (control or placebo group) for 4 weeks (Fig. 1).
The treatment began after a 1-week wash-out period for laxative
mediations.
2.3. Lax-Asab
Lax-Asab is a traditional herbal preparation (dried and powdered)
that contains equal proportions of Cassia angustifolia Vahl. (狹葉番瀉
葉 xia ye fan xie ye), Mentha piperita L. (胡椒薄荷 hú jiao bo he),
Zingiber ofﬁcinale Rosc. (生薑 sheng jiang), and Glycyrrhiza glabra L.
(甘草 gan cǎo). Because C. angustifolia is the only component with
laxative properties (the active component), the mixture of the other
three was used as the placebo. Thus, the placebo powder contained
the same intergradient as that of Lax-Asab, except C. angustifolia
leaves. Lax-Asab and placebo were supplied in identical containers
by Saeb-Darou Pharmaceutical Plant Company (Mashhad, Iran). The
powdered preparations were identical in appearance, taste, and
smell. All study personnel involved in the clinical evaluation and
patients were blinded to the study treatments. Patients ingested 1 g
of either Lax-Asab or placebo powder, which was provided in iden-
tical packages numbered by a study member blinded to clinical
evaluations. Patients dissolved the powder in one glass of boiled
water and ingested the medication before breakfast on alternative
days. Rescue medication was not allowed during the trial.
Noncompliance for 3 consecutive days or for a total of 7 days (self-
reported by study population) resulted in exclusion.
The dietary11 (Food Frequency Questionnaire) and physical ac-
tivities12 [International Physical Activity Questionnaire, last 7 days
(self-administered format)] of patients were controlled weekly
according to the standard questionnaire to maintain a constant
dietary composition and physical activity during the study. Side
effects were recorded each week, beginning with an open question
about any complaints and using a checklist asking about cramps,
abdominal pain, nausea, vomiting, diarrhea, gastric discomfort, and
excess bloating.
The severity of constipation (deﬁned as number of defecation
per week) and defecation difﬁculties (1 ¼ dry stool; 2 ¼ straining
force applied during defecation; and 3 ¼ obstruction during defe-
cation) were recorded before and after the trial.
2.4. Statistical analyses
Data were collected using checklists and the efﬁcacy of Lax-
Asab, determined by a symptom scale, was compared with that of
placebo during and at the end of the study. Data were analyzed
using SPSS version 16 (SPSS Inc., Chicago, IL, USA). Results are
presented as mean ± standard deviation. Chi-square, Fisher exact,
and independent t tests, and repeated measurements were used to
estimate differences wherever appropriate. A p value < 0.05 was
considered statistically signiﬁcant.
3. Results
Of the 60 chronic constipation patients assessed for eligibility,
48 patients were selected. The patients were randomly enrolled to
receive treatmentwith either Lax-Asab (n¼ 24) or placebo (n¼ 24).
A ﬂow diagram of the trial is presented in Fig. 1. Of these 48 pa-
tients, 40 completed the trial [24 men (60%), mean age, 21.0 ± 4.2
years; 16 women (40%), mean age, 20.1 ± 4.3 years]. The mean
weekly defecation time was 1.8 and 1.7 times, respectively, in pa-
tients receiving Lax-Asab and placebo (p ¼ 0.729).Most patients (n ¼ 32, 80%) had previously used at least one
medication for constipation in the past 6 months. The primary
complaint of patients was incomplete defecation followed by
abdominal bloating/distension, abdominal discomfort, and symp-
toms due to hemorrhoids.
The mean of weekly defecation times increased in both groups
(p ¼ 0.001); from 1.8 ± 0.41 to 4.8 ± 1.12 times in patients receiving
Lax-Asab and from 1.7 ± 0.44 to 2.2 ± 0.61 times in patients
receiving placebo. A timeetreatment interaction showed that this
increase was signiﬁcantly higher in the intervention group
(p < 0.0001). All the other measured outcomes concerning defeca-
tion difﬁculty were signiﬁcantly improved in patients receiving Lax-
Asab compared with placebo. The results are presented in Table 1.
No statistically signiﬁcant difference between the two groups
with regard to side effects was observed. Side effects were reported
by three patients who received placebo and by seven who received
Lax-Asab [odds ratio ¼ 3.05; 95% conﬁdence interval (0.65e14.13);
p ¼ 0.27]. Major side effects reported were watery diarrhea fol-
lowed by abdominal cramp, nausea, and distension in the inter-
vention group, and abdominal pain followed by distension in the
placebo group (Table 2). Other side effects such as allergic reaction
or drug-induced hepatitis were not observed/reported.
4. Discussion
This randomized, double-blind, placebo-controlled study sug-
gested the beneﬁts of Lax-Asab, a traditional herbal remedy con-
taining equal proportions of Cassia angustifolia Vahl. (狹葉番瀉葉
xia ye fan xie ye), Mentha piperita L. (胡椒薄荷 hú jiao bo he), Zin-
giber ofﬁcinale Rosc. (生薑 sheng jiang), and Glycyrrhiza glabra L. (甘
草 gan cǎo), which is used for the treatment of functional con-
stipation. This herbal preparation was well tolerated by our pa-
tients. In addition, the formulation increased the frequency of
defecation and decreased complaints as early as 2 weeks after
beginning the treatment.
There is no single deﬁnition of constipation. Patients mostly
deﬁne constipation by these symptoms: infrequent stools (typically
<3 times/wk), hard stools, the need for excessive straining force
during defecation, a sense of incomplete bowel evacuation, and
excessive time spent in the toilet or unsuccessful defecation. Herbal
preparations are commonly used in the symptomatic approach to
manage constipation.10 Leaves of senna (C. angustifolia Vahl.) have
been used as an alternative medicine and as an aid to treat con-
stipation. They contain anthraquinones that are known to have
stimulant laxative properties. However, no regulated
manufacturing standards for senna preparations exist yet. Not all
uses of senna are approved by the Food and Drug Administration,
and senna preparations are often sold as herbal supplements. There
are still not enough data to establish a doseeresponse relationship
but it has been reported that a combination of laxative and senna is
more efﬁcient in treating constipation.13 Senna leaves are well-
known for their laxative effects in Iran but their use is limited
due to the side effects, which can be very severe. Common side
Table 2
Side effects reported by the study patients.
No side effect Abdominal pain Nausea Diarrhea Distension Cramp Any side effect
Placebo 17 (85.0%) 2 (10.0%) 0 (0%) 0 (0%) 1 (5.0%) 0 (0%) 3 (15.0%)
Lax-Asab 13 (65.0%) 0 (0%) 1 (5.0%) 3 (15.0%) 1 (5.0%) 2 (10.0%) 7 (35.0%)
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dration, and diarrhea accompanied by cramps. However, in this
study, Lax-Asab, an herbal formulation that contains senna leaves
along with other herbal ingredients in equal proportions, effec-
tively decreased defecation problems and the patients did not
experience any serious side effects.
Ginger (Z. ofﬁcinale Rosc.) is a well-known ﬂavoring agent in the
East and has been traditionally used for GI upsets. Ginger prepa-
rations have been reported to be effective against nausea associated
with motion sickness and chemotherapy.14 Human studies and
clinical trials of peppermint leaf (M. piperita L.) are limited. How-
ever, peppermint has a relaxing effect on GI tissue, as well as
analgesic and anesthetic effects on the central and peripheral
nervous systems in animal models.15 The ﬁnal ingredient of Lax-
Asab, G. glabra L., has various pharmacological properties,
including antitumor, antiparasitic, antiulcer, and antioxidative ef-
fects.16 Despite the fact that it is has been traditionally used in the
preparation, none of these properties seemed efﬁcient at reducing
the side effects or increasing the efﬁcacy of the preparation. Further
studies may include several study arms to clarify this.
Although we did not use a satisfaction questionnaire, none of
participants stopped using Lax-Asab because of bad taste or intol-
erable side effects. The herbal combination seems to limit the side
effects of senna while giving a tolerable taste. However, this is only
a preliminary study and further studies for determining the dosage
are necessary.
Speculations about complementary and alternative medicines
producing only a placebo effect still exist. However, similar to other
studies that evaluated the efﬁcacy of herbal preparations in treating
functional constipation, a very low placebo effect was observed in
this study.17
Safety analysis revealed that there were no statistically signiﬁ-
cant differences in side effects between the two groups. Adverse GI
events included abdominal distension, pain, diarrhea, ﬂatulence,
and nausea; their incidence was not different between the two
groups. In addition, the side effects were not considered to be
related to the study medication.
Although the main signiﬁcance of these ﬁndings could be
providing evidence about the efﬁcacy of this preparation for clini-
cians, so they can use this formulation in their practice with func-
tional constipation patients, these results could be a base for
further research to optimize preparations based on senna,
involving identifying the exact dosage required and the effects of
other ingredients. In addition, although this study did not evaluate
the ﬁnancial beneﬁts of using Lax-Asab, this preparation will
obviously cost less, given the fact that patients face a chronic
condition lasting for several months, which requires expensive
medications otherwise. By contrast, the aforementioned herbal
ingredients are low priced and widely available.
A possible limitation of this study is that although we evaluated
the changes in bowel movements (determined based on frequency
of defecations), other potentially related variables such as stool
consistency, stool weight, and ease of defecation were not evalu-
ated. In other words, measurements were limited to subjective
reports, and objective evaluations, whichwould be time consuming
and costly, were not feasible. However, these results would have
clinical relevance as subjective complaints have a very important
impact on the everyday life of patients, especially in those withfunctional disorders. Another limitation was the short duration of
follow up, whichwas a result of the preliminary nature of this study
and should be improved in further studies that could target cost
effectiveness as well.
5. Conclusion
This study provides evidence for the safe and effective use of
Lax-Asab in treating chronic functional constipation.
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